Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial

Go Back to All Clinical Trials

Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial

Brief description of study

The purpose of this research study is to assess the safety of daratumumab (Darzalex®) and whether it may reduce levels of antiphospholipid antibodies, a blood protein in the immune system that mistakenly creates antibodies that attack tissues in the body, in patients with antiphospholipid syndrome (APS).

Clinical Study Identifier: s22-01215

ClinicalTrials.gov Identifier: NCT05671757

Principal Investigator: Howard Belmont.

Other Investigator: Janine M. Sullivan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies